Posted by Michael Wonder on 02 Oct 2020
FDA grants fast track status to Aegle Therapeutics' AGLE-102 for the treatment of dystrophic epidermolysis bullosa
1 October 2020 - Aegle Therapeutics Corporation today announced the U.S. FDA has granted fast track designation to AGLE-102 for the treatment of patients with dystrophic epidermolysis bullosa, a rare genetic paediatric skin blistering disorder.
AGLE-102 is an extracellular vesicle therapy that delivers proteins, genetic material and regenerative healing factors to diseased and damaged tissue.
AGLE-102 will be evaluated in patients with dystrophic epidermolysis bullosa in a Phase 1/2a trial initiating in 2021.
